Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Monday, October 30, 2023
An update from the phase III NeoTRIP Michelangelo study investigating the addition of neoadjuvant atezolizumab to carbolatin/nab-paclitaxel as therapy for patients with high-risk triple-negative breast cancer was presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA19). Luca Gianni, MD, of Fondazione Michelangelo, Milan, Italy, and colleagues, reported that this therapeutic strategy did not improve event-free survival in this patient population, although it had .
“PD-L1 expression and higher stromal tumor-infiltrating lymphocytes at baseline were prognostic for better event-free survival but not predictive of atezolizumab benefit,” the investigators stated.
The study included 280 patients with early-stage, high-risk or locally advanced triple-negative breast cancer. All patients received neoadjuvant carboplatin and nab-paclitaxel but were randomly assigned to receive atezolizumab. A total of 138 patients received atezolizumab, and 142 received carboplatin plus nab-paclitaxel alone.
The 5-year event-free survival rate was 70.6% with atezolizumab and 74.9% without atezolizumab, at a median follow-up of 54 months. A P value of .66 was reported on stratified analysis by disease state, PD-L1 expression, and age. The investigators reported that during follow-up, no new safety signals possibly related to atezolizumab were observed.
Biomarker analysis is ongoing in an attempt to identify patients who may benefit from the addition of atezolizumab.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
Resources
For your Patients
